BIOCRYST PHARMACEUTICALS, INC. Long-term Line of Credit
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Long-term Line of Credit of $0 as of 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LineOfCredit · last filed 2021-03-01
- 2020-12-31: Long-term Line of Credit $0.00.
- 2020-09-30: Long-term Line of Credit $26.89M.
- 2020-06-30: Long-term Line of Credit $31.71M.
- 2020-03-31: Long-term Line of Credit $36.51M.
| Period end | Long-term Line of Credit |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 |
| 2020-09-30 | $26.89M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $31.71M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $36.51M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $41.29M 10-K · filed 2021-03-01 |
| 2019-09-30 | $46.04M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $49.85M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $49.62M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $25.37M 10-K · filed 2020-03-13 |
| 2018-09-30 | $28.29M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $13.47M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $15.11M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $16.75M 10-K · filed 2019-03-14 |
| 2017-09-30 | $18.38M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $20.00M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $21.61M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $22.78M 10-K · filed 2018-03-12 |
| 2016-09-30 | $22.66M 10-Q · filed 2016-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |